Powder: -20°C for 3 years | In solvent: -80°C for 1 year
K783-0308 is a potent and selective MNK2 and FLT3 dual inhibitor with IC 50 values of 406 and 680 nM, respectively. K783-0308 promotes the apoptosis and cell cycle arrests in the G0/G1 phase of acute myeloid leukemia (AML) cell. K783-0308 inhibits the MV-4-11 and MOLM-13 cell growth with IC50 values of 10.4 and 10.5 μM, respectively [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | K783-0308 is a potent and selective MNK2 and FLT3 dual inhibitor with IC 50 values of 406 and 680 nM, respectively. K783-0308 promotes the apoptosis and cell cycle arrests in the G0/G1 phase of acute myeloid leukemia (AML) cell. K783-0308 inhibits the MV-4-11 and MOLM-13 cell growth with IC50 values of 10.4 and 10.5 μM, respectively [1]. |
In vitro | K783-0308 (MOLM-13, MV-4-11 cells) shows cytotoxic effect against MOLM-13 (IC 50 =10.5 μM) and MV-4-11 (IC 50 =10.4 μM) cells [1]. K783-0308 (1, 3, 10, 30 μM) promotes AML cell apoptosis and cell cycle arrests in the G0/G1 phase [1]. Cell Cytotoxicity Assay [1] Cell Line: MOLM-13, MV-4-11 cells (RPMI-1640 supplemented with streptomycin (100 μg/mL)/penicillin (100 U/mL)/ amphotericin B (0.25 μg/mL)) Concentration: 1, 3, 10, 30 μM Incubation Time: 48 h, 72 h Result: Promotes AML cell apoptosis and cell cycle arrested in the G0/G1 phase. |
Molecular Weight | 333.43 |
Formula | C21H23N3O |
CAS No. | 422554-29-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
K783-0308 422554-29-8 inhibitor inhibit